News and reporting on lung cancer.
The FDA has granted accelerated approval to Rozlytrek as a treatment for adult and adolescent patients with NTRK fusion-positive cancers.
The firm, which is working to reaccelerate its test validation effort, incurred a loss of $5.4 million, or $.10 per share, slightly above the analysts' consensus estimate.
Researchers developed a microfluidic device that combines antibody-based cell capture and disulfide cleavage for downstream microRNA detection.
Researchers focused on candidate genes near expression quantitative trait loci identified by combining cancer susceptibility SNPs and available transcriptomic data.
In PLOS this week: variations in the way synonymous DNA codons are used in yeast, links between germline TP53 mutations and recurrent somatic mutations in bladder cancer, and more.
The firm has joined forces with AstraZeneca, the IASLC, and the Global Lung Cancer Coalition, with a goal to double five-year survival rates by 2025.
Re-expression of DUX4, which is normally silenced in somatic tissues, appeared to stymie MHC class I-related immune activity in several solid cancer types.
The study plans to recruit close to 300 patients with advanced non-small cell lung cancer, with half being treated based on liquid biopsy results.
A proof-of-principle study suggests metabolite clusters may differ in non-small cell lung cancer patients depending on tumor type, disease stage, and overall survival trajectory.
The company will market Inivata's InVision liquid biopsy assays to insured and self-pay patients across the region.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.